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Abstract
Background—C-reactive protein (CRP) is increasingly measured as a marker of systemic 
inflammation that predicts elevated risk for cardiovascular disease. Influenza vaccination is a mild 
pro-inflammatory stimulus, and the CRP response to vaccination may provide additional 
information on individual differences in inflammatory response and risk for disease.
Aim—To document the pattern of CRP response to influenza vaccination among a large sample 
of older women in the Philippines. The Philippines exemplifies current global trends toward 
increasing rates of overweight/obesity, but also maintains relatively high rates of infectious 
disease. The secondary aim of the study is to investigate the impact of infectious symptoms on the 
pattern of response to vaccination.
Methods—A community-based sample of 934 women (mean age=55.4 years) received the 
influenza vaccine. CRP was assessed at baseline and 72 hours post-vaccination. Descriptive, non-
parametric, and parametric analyses were implemented to assess the magnitude of CRP response, 
and to investigate whether responses were associated with baseline CRP or the presence of 
infectious symptoms prior to vaccination.
Results—Influenza vaccination resulted in a statistically significant CRP response of 0.35 mg/L 
(p<0.001), representing a 30.2% increase from baseline. For individuals with symptoms of 
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infectious disease at baseline, the CRP response was smaller (12.9%) and not statistically 
significant (p=0.77). Lower CRP at baseline was associated with larger CRP response to 
vaccination in the entire sample, and among participants without recent symptoms of infection.
Conclusions—Influenza vaccination produces a mild CRP response in the Philippines. This 
study extends prior research in US and European populations validating influenza vaccination as 
an in vivo model for investigating the dynamics of inflammation, but also raises potential 
complications in settings where rates of infectious disease are elevated.
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1. Introduction
Inflammation has been implicated in multiple aspects of atherosclerosis, and C-reactive 
protein (CRP) is widely measured epidemiologically and clinically as an end-point marker 
of systemic inflammation that predicts elevated risk for incident cardiovascular disease [1], 
type 2 diabetes [2], late-life disability [3], and all-cause mortality [4-7]. As a prototypical 
acute phase protein, CRP is produced in response to pro-inflammatory cytokine signals, and 
concentrations increase acutely as part of innate immune responses to infection or injury 
[8-10]. Vaccination provides an opportunity to investigate individual differences in acute 
inflammatory responses which may provide additional information on disease risk beyond 
what can be obtained from baseline measures of systemic inflammation [11-13].
Recently, the influenza vaccine has been proposed as an in vivo model for probing mild 
stimulation of inflammatory processes. Among healthy older adults in the Netherlands [14] 
and the US [15], influenza vaccination resulted in small, but significant increases in CRP 
one to three days post-vaccination. In men with carotid artery disease, the CRP response to 
vaccination was 1.3 times greater than the response in healthy controls [16], and distinct 
patterns of response have been reported in patients with stable versus unstable forms of 
coronary heart disease [17]. Exaggerated inflammatory responses to influenza vaccination 
have also been associated with greater depressive symptoms in older adults [13], and among 
pregnant women [18]. These studies underscore the potential value of influenza vaccination 
as a mild, controlled stimulus for investigating individual differences in inflammatory 
responses in vivo.
The objective of this study is to document the pattern of CRP response to influenza 
vaccination among older women in the Philippines. Prior studies on the inflammatory 
response to vaccination, and on the associations among inflammation and cardiovascular 
disease more broadly, have been conducted primarily in high income American and 
European settings. Comparative data from a broader range of populations are needed since 
85 percent of the global burden of cardiovascular disease now rests on the shoulders of low 
and middle income nations [19]. In addition, many of these nations are experiencing double 
burdens of disease: rising rates of cardiovascular and metabolic diseases are supplementing, 
rather than supplanting, infectious diseases as ongoing contributors to morbidity and 
mortality [20,21]. Given the important role CRP plays in the acute phase response to 
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infection, a higher prevalence of infectious disease may complicate efforts to apply 
vaccination as an in vivo model of inflammatory response.
Lastly, the dynamics of inflammation may differ across populations in ways that influence 
the response to vaccination. For example, in prior work we reported that baseline CRP 
concentrations among healthy adults in the Philippines are significantly lower than in the US 
[22,23], and that higher levels of microbial exposure in infancy may contribute to lower 
levels of chronic inflammation [24]. It is therefore important to investigate whether the CRP 
response to an inflammatory challenge is similar to what has been reported in similar studies 
in US and European contexts. Furthermore, prior research has indicated that the CRP 
response to vaccination is independent of baseline CRP [16], but whether this is a universal 
phenomenon is not known.
The Philippines is a lower-middle income nation that exemplifies current global trends 
toward increasing rates of overweight/obesity, cardiovascular diseases, and the metabolic 
syndrome as a result of economic, dietary, and lifestyle transitions [25-27]. At the same 
time, infectious disease remains a significant source of morbidity and mortality, with 
respiratory infections ranking along with ischemic heart disease as the top causes of death 
[28]. The specific objectives of this paper are threefold: 1) To document the magnitude of 
CRP response to influenza vaccination in a large sample of older adult women in the 
Philippines; 2) To investigate the impact of infectious symptoms prior to vaccination on the 
pattern of response; and 3) To evaluate the association between baseline CRP concentrations 
and the magnitude of vaccine response. Results from this study may shed light on the utility 
of influenza vaccination as an in vivo model for investigating the dynamics of inflammation 
among adults around the world.
2. Materials and Methods
Participants and study design
The Cebu Longitudinal Health and Nutrition Survey (CLHNS) began in 1983 with the 
recruitment of a community-based sample of 3327 pregnant women. The CLHNS objectives 
and survey design have been described previously [29]. The data for the present analyses 
come from the most recent survey, conducted between 2012-2013, which enrolled 1818 
women, or 55% of the original sample. Of these, 967 were administered the influenza 
vaccine through intramuscular injection, using the 2012 Southern Hemisphere composition 
(Sanofi Pasteur, Vaxigrip single dose, 0.5 mL). The vaccine study was implemented 
between April and December 2012, the period of time between the release of the vaccine in 
the Philippines and its expiration. Participants were screened by study physicians in local 
health centers prior to vaccination. Individuals with fever or other sickness on the day of 
vaccination were rescheduled. N=851 (46.8%) were not vaccinated for the following 
reasons: Enrollment after vaccine expiration date (n=316), refusal (n=215), difficulty 
scheduling vaccination (n=164), or ineligibility (n=115; recently vaccinated, allergic to egg/
chicken, or other health condition).
The final sample included N=934 women with CRP results at baseline and day 3. The 
average time between vaccination and day 3 blood sampling was 72.1 hours, with 95 percent 
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of blood samples collected between 72.0 and 72.5 hours, and all samples collected between 
71 and 74 hours post-vaccination. Baseline blood samples were collected immediately prior 
to vaccination (mean time between blood sampling and vaccination = 11.8 minutes). All 
data were collected under conditions of informed consent with institutional review board 
approval from the University of North Carolina, Chapel Hill and the Office of Population 
Studies Foundation at the University of San Carlos, Cebu.
Blood samples were collected as finger stick capillary whole blood, dried on filter paper 
(dried blood spots, DBS) for the analysis of CRP. Each participant's finger was cleaned with 
alcohol, and a sterile, disposable microlancet was used to deliver a controlled, uniform 
puncture. Whole blood was placed directly on standardized filter paper commonly used for 
neonatal screening (Whatman #903, GE Healthcare, Pascataway, NJ). This relatively non-
invasive blood collection protocol minimizes pain and inconvenience to the participants, and 
facilitates the collection of repeat blood samples despite the constraints of field-based 
research settings [30]. After collection, DBS cards were allowed to dry at ambient 
temperatures for approximately four hours, and were stored in gas impermeable bags at 
−20°C prior to shipment. Samples were express shipped to the U.S. where they were stored 
at −30°C prior to analysis.
Measurement of CRP
Samples were analyzed for CRP in the Laboratory for Human Biology Research at 
Northwestern University using a modified high sensitivity enzyme immunoassay protocol 
previously developed for use with DBS [31]. Prior validation of assay performance indicates 
that the DBS CRP method produces results that are comparable to gold standard plasma-
based clinical methods, with a lower limit of detection of 0.03 mg/L [31]. To minimize 
between-assay variation, all samples were analyzed by the same technician using a single lot 
of capture antibody, detection antibody, and calibration material. In addition, baseline and 
day 3 samples for each individual were included on the same assay plate in order to enhance 
within-individual comparisons. Between-assay CVs for low, mid, and high control samples 
included with all runs were 9.6%, 8.7%, and 10.6%, respectively.
Analysis of DBS samples provides concentrations of whole blood CRP, which will differ 
from plasma CRP due to the presence of lysed erythrocytes and associated matrix effects. 
However, since DBS and plasma results are highly correlated a conversion formula can be 
applied to DBS CRP results to calculate plasma equivalent values [32]. We converted DBS 
results into plasma equivalent values using a study-specific conversion formula based on 
n=69 matched DBS and plasma samples, collected for a prior assay validation study. DBS 
samples were analyzed using the same procedures, lot number of reagents, and technician as 
applied to the study DBS samples. Plasma samples were analyzed for high sensitivity CRP 
in a high throughput clinical laboratory (NorthShore Research Institute), on the Beckman 
Coulter Synchron DXC platform. The correlation between DBS and serum values was high 
(Pearson R = 0.98) and the resulting Deming regression conversion formula was as follows: 
plasma (mg/L) = 1.64 x DBS (mg/L).
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The distribution of CRP values was highly skewed at baseline and day 3, and values were 
therefore log transformed (base 10) to normalize the distribution. However, descriptive 
analyses and statistical tests were implemented using untransformed as well as transformed 
results to confirm similar patterns of results. Non-parametric tests of differences in medians 
were implemented using Wilcoxon matched-pairs signed-ranks and rank sum tests, and 
Spearman rank-order correlation was used to assess strength of association. Log-transformed 
results were subjected to paired t tests, Pearson correlation, and ordinary least squares 
regression analyses.
At baseline, prior to vaccination, participants were asked whether had been sick in the last 
week. Participants reported their symptoms, and a dichotomous variable indicating the 
presence of infectious symptoms was created with a value of 1 for any of the following 
symptoms: diarrhea, urinary tract infection, body aches, fever, cold, vomiting, pneumonia, 
sinusitis, tonsillitis, sore throat, or open wound. Individuals were not vaccinated if they had 
fever (>37.5°C) or sickness on the day of vaccination; therefore this variable represents 
recent symptoms of infectious disease, in the week prior to vaccination. Sign rank and t tests 
were implemented to investigate differences in CRP response to vaccination associated with 
the presence or absence of infectious symptoms at baseline.
Additional anthropometric data were collected using standard techniques [33], and 
demographic and health-related information was collected during baseline interviews to 
characterize the sample. A daily smoker was defined as one or more cigarettes/day, each day 
of the week. Participants were also asked to report any medications they were currently 
taking, and a summary variable indicating the use of anti-inflammatory medication was 
constructed based on the following MIMS sub-classes [34]: GIT regulators, antiflatulents, 
and anti-inflammatories; analgesics (non-opioid) and antipyretics; nonsteroidal anti-
inflammatory drugs (NSAIDs); corticosteroid hormones. Hormone replacement therapy 
(N=2) and statins (N=12) were not reported with sufficient frequency for analysis.
3. Results
Magnitude of CRP response to vaccination
The average age of participants was 55.4 years, with low rates of smoking (8.6%) and anti-
inflammatory medication use (4.5%) (Table 1). At the time of vaccination 7.0% of 
participants reported one or more symptoms of infectious disease.
For the entire sample, median CRP concentration at baseline was 1.16 mg/L, which is in the 
low end of the range for “average risk” [4]. Median CRP three days post-vaccination was 
1.51 mg/L, which is an increase of 0.35 mg/L, or 30.2% (Figure 1). Post-vaccination 
concentrations of CRP were significantly higher according to the Wilcoxon test for 
differences in medians (z=8.96, p<0.001), and the paired t test for differences in mean 
logCRP (t=10.26, p<0.001).
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Symptoms of infection and CRP response to vaccination
Sixty five participants (7.0%) reported symptoms of infectious disease during the week 
preceding vaccination, and as expected, infectious symptoms were associated with elevated 
CRP. Median CRP was 1.70 mg/L at baseline for participants reporting infectious 
symptoms, compared with 1.12 mg/L for participants without infectious symptoms (z=
−3.312, p<0.001). Participants with recent infectious symptoms did not differ from the rest 
of the sample with respect to age, level of education, waist circumference, smoking status, 
or urban residence (all p>0.28). They were, however, almost three times more likely to have 
taken anti-inflammatory medication (12.3% vs. 3.9%, Pearson chi square = 9.92, p<0.01) in 
the preceding week. However, this group was small: Only eight participants reported recent 
infectious symptoms and anti-inflammatory medication use.
In the absence of recent symptoms of infection, day 3 median CRP was 1.47 mg/L, a 31.2% 
increase from 1.12 mg/L at baseline. Wilcoxon test for differences in medians (z=9.31, 
p<0.001), and the paired t test for differences in mean logCRP (t=10.46, p<0.001), indicated 
that this was a statistically significant increase. Results were virtually identical when 
participants reporting anti-inflammatory medication use (N=34) were removed from the 
sample.
The CRP response to vaccination was attenuated among participants reporting recent 
infectious symptoms: median CRP at day 3 was 1.92 mg/L, representing a 12.9% increase 
from the baseline median of 1.70 mg/L. Tests for difference in median CRP (z=0.288, 
p=0.77) and mean logCRP (t=0.84, p=0.40) indicated that the increase in CRP following 
vaccination was not statistically significant for individuals reporting infectious symptoms. 
The pattern of CRP response was virtually identical when participants reporting anti-
inflammatory medication use (N=8) were removed.
Baseline CRP and response to vaccination
We next investigated whether baseline CRP concentration affected the magnitude of the 
CRP response to vaccination. Since recent symptoms of infectious disease were associated 
with elevated CRP at baseline, we removed participants with infectious symptoms from 
these analyses. We divided the sample into baseline CRP groups according to the 
distribution of values in the sample. We then determined the CRP response for each 
individual (CRPDay 3 – CRPbaseline) and calculated the median response within each group 
in mg/L, and as a percentage of baseline (CRPresponse/CRPbaseline) (Table 2). When baseline 
CRP was ≤ 3.0, the response to vaccination was positive and ranged from 0.10 to 0.32 mg/L. 
At higher concentrations of baseline CRP, the median response was negative, with 
substantially lower CRP at Day 3.
At baseline, 22.4% of the sample had CRP ≤ 0.5 mg/L, and the median response to 
vaccination was relatively low at 0.10 mg/L. However, when considered as a percentage of 
baseline, the magnitude of response was 34.0%. The percent response was 38.9% for 
baseline CRP > 0.5 to ≤ 1.0, and then decreased with higher baseline CRP and became 
negative for CRP > 3.0 mg/L. Spearman's rank correlation confirms that higher baseline 
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CRP is significantly associated with lower CRP response to vaccination, in terms of mg/L 
(rho = −0.12, p<0.001) and percent response (rho = −0.34, p<0.001).
We confirmed this pattern of results with logCRPresponse, which is negatively correlated 
with logCRPbaseline (Pearson R = −0.33, p<0.001). In regression models we added a 
quadratic term (logCRPbaseline2) since the results above suggested the possibility of a non-
linear association between baseline CRP and vaccine response. LogCRPbaseline is a 
significant predictor of logCRPresponse (B = −0.205, SE=0.020, p<0.001), as is the quadratic 
term (B = −0.054, SE=0.027, p<0.05). As shown in figure 2, CRP response to vaccination is 
highest at low baseline CRP concentrations, and becomes increasingly attenuated with 
higher baseline CRP. The pattern of association between baseline CRP and response to 
vaccination was virtually identical when individuals with recent symptoms of infectious 
disease were included. Similarly, when we added the variables in Table 1 as predictors of 
logCRPresponse, the pattern of association with logCRPbaseline was unchanged. In addition to 
logCRPbaseline, waist circumference was a significant predictor of vaccine response (B = 
0.002, SE=0.001, p<0.05).
4. Discussion
Dynamic measures of inflammation may provide important insights into individual 
differences in the regulation of inflammation and risk for disease [11,14,16]. Results from 
this study extend prior research in affluent US and European populations validating 
influenza vaccination as an in vivo model for investigating the inflammatory response to 
mild stimulation. We confirm that influenza vaccination induces a mild acute inflammatory 
response, but we also report attenuated responses in relation to infectious symptoms and 
higher baseline CRP, findings that may have important implications for applying the vaccine 
model in future research, particularly in epidemiologic settings with elevated rates of 
infectious disease.
In our sample of older women in the Philippines the pattern of CRP response to vaccination 
is similar in magnitude to prior research [14-16]. The increase in CRP is modest but 
significant at 0.35 mg/L, representing a 30.2% increase from baseline. This response is 
larger than the 0.20 mg/L increase reported in the Netherlands [14], and smaller than the 
40-63% increase among older adults in two recent studies in the US [15,16].
To the best of our knowledge, this study is the first to document differences in CRP response 
to influenza vaccination in relation to symptoms of infectious disease and baseline 
concentrations of CRP. In their study of 38-88 year-old men, Carty et al. [16] report no 
association between baseline CRP and the magnitude of response to vaccination. We find a 
significant negative association, with the highest CRP responses among participants with 
lower CRP at baseline. We also find attenuated, and statistically insignificant, responses 
among participants reporting symptoms of infectious disease in the week preceding 
vaccination.
It is well established that CRP concentrations increase as part of the acute phase response to 
a wide range of pathogens [8,35], and the CRP response to vaccination may therefore be 
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obscured in participants with prior infectious symptoms. A similar process may explain the 
negative association between baseline CRP and vaccine response: Although the reported 
frequency of infectious symptoms in our sample was 7.0%, it is likely that the level of 
subclinical infection was substantially higher. If elevated CRP at baseline was due to the 
presence of infectious symptoms—reported or not—then the negative association between 
baseline CRP and response to vaccination may reflect resolution of an active acute phase 
response that was in process the week preceding vaccination.
Alternatively, the CRP response to vaccination may provide insight into stable individual 
differences in the regulation of inflammation. The combination of low baseline CRP and 
robust increases in response to challenge may represent the optimal pattern, whereby acute 
responsiveness to infection is maximized but risk for diseases associated with chronic 
inflammation is minimized. In contrast, lack of response to vaccination may signal a poorly 
regulated inflammatory system that increases risk for disease. Previously, we have shown 
that higher levels of microbial exposure during infancy predict lower levels of chronic 
inflammation in the Philippines [24,36], consistent with a wider literature documenting the 
importance of microbial exposure to the development of immunoregulatory networks during 
critical periods of development [37-39]. In this context, it is interesting to consider whether 
the absence of correlation between baseline CRP and vaccine response reported in the US 
reflects a distinct pattern of regulation that is the result of lower levels of microbial exposure 
in infancy and higher levels of chronic inflammation in adulthood.
Limitations of the study include the exclusive focus on women, and the use of a single post-
vaccination CRP measure. Prior research has suggested that the inflammatory response to 
vaccination may peak at 48 hours [14], although other studies have followed up after 24 or 
72 hours [15,16], and it would have been preferable to have multiple measures of response 
over time. A major strength is the large, community-based sample which enhances external 
validity, and provides opportunities for investigating the long term association between CRP 
responsiveness and risk for disease. Follow up studies will be particularly important for 
determining if measures of inflammatory response provide predictive value above and 
beyond currently recommended measures of baseline chronic inflammation [4].
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CRP response to influenza vaccination. Median concentrations of CRP at baseline and three 
days following vaccination (error bars represent 25th and 75th percentile values).
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Scatterplot of CRP response to vaccination in relation to baseline CRP concentration.
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Table 1
Baseline characteristics for study participants (n=934).
Total
Age (years) 55.4 ± 5.9
Education (highest grade) 7.1 ± 3.5
Waist circumference (cm) 81.9 ± 11.1
Urban residence (%) 82.6
Daily smoker (%) 8.6
Current infection (%) 7.0
Anti-inflammatory medication (%) 4.5
Values are mean ± standard deviation for continuous variables.
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Table 2
CRP response to vaccination in relation to baseline CRP concentrations (N=869; participants with recent 
symptoms of infection excluded from analysis).
Baseline CRP N median CRP response, mg/L (range) median CRP response, % of baseline (range)
≤0.5 mg/L 195 0.10 (−0.19, 25.55) 34.0 (−60.0, 17504.5)
>0.5 to ≤1.0 194 0.28 (−0.70, 30.01) 38.9 (−96.9, 3960.6)
>1.0 to ≤2.0 223 0.32 (−1.13, 19.76) 24.6 (−70.8, 1806.4)
>2.0 to ≤3.0 109 0.24 (−1.68, 56.6) 10.1 (−71.1, 2553.3)
>3.0 to ≤5.0 93 −0.27 (−3.01, 45.45) −6.0 (−68.8, 1245.4)
>5.0 to ≤10.0 44 −1.39 (−4.83, 7.55) −19.6 (−73.8, 110.9)
>10.0 11 −8.35 (−32.41, 13.62) −34.1 (−85.0, 88.1)
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